Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?
The global range and high fatality rate of the newest human coronavirus (HCoV) pandemic has made SARS-CoV-2 the focus of the scientific world. Next-generation sequencing of the viral genome and a phylogenetic analysis have shown the high homology of SARS-CoV-2 to other HCoVs that have led to local e...
Main Authors: | Emilia Sinderewicz, Wioleta Czelejewska, Katarzyna Jezierska-Wozniak, Joanna Staszkiewicz-Chodor, Wojciech Maksymowicz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Pathogens |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-0817/9/9/739 |
Similar Items
-
Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01) -
Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01) -
SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01) -
The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
by: Yun-yu Zhang, et al.
Published: (2020-08-01) -
Convalescent plasma as a therapeutic agent for SARS-CoV, MERS-CoV and SARS-CoV-2: A scoping review
by: Abeba Haile Mariamenatu, et al.
Published: (2021-01-01)